I think the event that will trigger the CC is filing the IND. The content will also include an update on Neurology's completion of their review of CX717; progress with other low-impacts like CX701, and the status of the high-impact program. The kind of information that Cortex shareholders used to demand, and complain when it wasn't forthcoming. There might be a 5% chance of a partnership, a 20% chance of an inlicensing. I see little likelihood that there will be a PIPE announced, as I stated earlier, the timing would be virtually indefensible.
It's interesting to me that, having posted a comparison with Targacept's even more precipitous drop, there was, so far as I can tell, zero response on this Board to that comparison. I could mention Neurogen, whose share price has plummeted in spectacular fashion without any clear precipitant. In neither of those cases, has there been any reason to expect a PIPE...there has been an exit for reasons that strike me as sectoral profit-taking, not due to individual company dynamics (other than the fact that there was a profit to be taken). The difference for Cortex is the warrant conversion, where a sectoral retreat becomes temporarily amplified by conversions and sales. But that also will provide cash, making a PIPE even more unlikely.
Cortex shareholders and observers can, if they choose, continue to torture themselves with a search for some hidden agenda, some secret that we will be the last to know. Occam's razor--the law of parsimony--suggests that adding extraneous explanatory hypotheses does not improve the accuracy of the guesswork. And most of the conjectures offered of late smack of the extraneous, IMHO.
NeuroInvestment
Market Data 
Markets 
AI
